How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies - ESMO Open
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 - Annals of
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer | npj Breast Cancer
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | British Journal of Cancer
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
Definitive Proof that Dose-Dense Chemotherapy Is Safe and Effective for Breast Cancer | Memorial Sloan Kettering Cancer Center
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies - ScienceDirect
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text
![PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cad0421203b35bdec3bcffd87abb3ca1fd4c1ef4/7-Figure3-1.png "PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar")
PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial - Annals of Oncology
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
1869-Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense | eviQ
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose Dense-Intensive Chemotherapy Improves Survival in Early Stage Breast Cancer - CancerConnect
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
